Skip to main content
Clinical Trials/NCT05832372
NCT05832372
Not yet recruiting
Not Applicable

Esophagogastric Histopathology Potentially Guided Patients Younger Than 50 Years Old to Undergo Colonoscopy Earlier: A Retrospective Cross-sectional Study

Shandong University0 sites9,000 target enrollmentMay 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Neoplasms
Sponsor
Shandong University
Enrollment
9000
Primary Endpoint
Prevalence or occurrence of upper gastrointestinal diseases
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Colorectal cancer (CRC) is the third most diagnosed cancer worldwide and second leading cause of cancer death. Most CRCs arise from a polyp, developing through two major precursor lesion pathways: the traditional adenoma-carcinoma pathway, and the serrated neoplasia pathway. This provides opportunities to prevent cancer by removing its precursor lesions. CRC screening efforts are directed toward removal of precancerous polyps with colonoscopy and detection of early-stage CRC, which has been demonstrated to reduce CRC incidence and mortality effectively, making CRC one of the most preventable and treatable forms of cancer.

Current guidelines in China recommend starting CRC screening uniformly at age 50 in average-risk individuals. However, a one-fits-all approach to determining CRC screening starting age may be not conducive to personalized screening, especially in the developing countries with scarce health resources. The incidence of early-onset CRC (CRC diagnosed before the age of 50) has shown a continuous increasing trend worldwide, spurring the US Preventive Services Task Force to recommend initiating average-risk CRC screening at age 45 instead of 50. Furthermore, different populations may benefit from even earlier screening, and CRC incidence may differ on the basis of population characteristics and CRC risk factors. For individuals younger than 50 years old, earlier screening based on risk factors may address this concern.

Previous studies have recommended earlier starting age of CRC screening combined with risk factors such as but not limited to sex, age, family history, lifestyle and comorbidity. Some upper gastrointestinal diseases have also been reported to be associated with an increased risk of colorectal neoplasms, which may be related to the destruction of gastric acid barrier function and long-term use of pump proton inhibitors. Compared with colonoscopy examination, individuals were more willing to undergo esophagogastroduodenoscopy (EGD) examination for gastric cancer screening, especially among the younger, potentially utilizing the EGD to guide earlier colonoscopies for patients at increased risk. Therefore, this study was aimed to investigate the association between esophagogastric histopathology and colorectal neoplasms in patients under the age of 50 and whether these risks factor could be combined with to guide earlier CRC screening.

Registry
clinicaltrials.gov
Start Date
May 1, 2023
End Date
May 27, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Shandong University
Responsible Party
Principal Investigator
Principal Investigator

Yanqing Li

Clinical Professor

Shandong University

Eligibility Criteria

Inclusion Criteria

  • Patients younger than 50 years old who underwent gastroscopy and colonoscopy simultaneously.

Exclusion Criteria

  • Patients without a good bowel preparation (Boston Bowel Preparation Scale \[BBPS\] score ≥ 6);
  • Incomplete gastroscopy or colonoscopy examinations;
  • Partial or total gastrointestinal resection;
  • Patients who have been diagnosed with gastrointestinal cancer before endoscopy;
  • Hereditary polyposis, including Peutz-Jeghers syndrome, and familial adenomatous polyposis;
  • A history of inflammatory bowel diseases.

Outcomes

Primary Outcomes

Prevalence or occurrence of upper gastrointestinal diseases

Time Frame: 1 year

Including Helicobacter pylori, atrophic gastritis/intestinal metaplasia, reflux esophagitis, Barrett's esophagus, peptic ulcer, gastric polyps, low-grade intraepithelial neoplasia (LGIN), and high-grade intraepithelial neoplasia (HGIN).

Similar Trials